



Gossamer Bio Announces Participation in Upcoming Investor Conferences

February 22, 2019

SAN DIEGO--(BUSINESS WIRE)--Feb. 22, 2019-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the following upcoming investor conferences:

- 8th Annual SVB Leerink Healthcare Conference on Wednesday, February 27 at 11:00 a.m. ET.
- Barclays Global Healthcare Conference on Wednesday, March 13 at 3:50 p.m. ET.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190222005054/en/>

Source: Gossamer Bio, Inc.

For Investors:

Argot Partners
Kimberly Minarovich
Tel 212.600.1902
kimberly@argotpartners.com

For Media:

Argot Partners
David Rosen
Tel 212.600.1902
david.rosen@argotpartners.com